Combination treatment with a selective proteasome inhibitor, VELCADE, and low-dose rt-PA could reduce infarction volume with an associated increase in endothelial nitric oxide synthase activity compared to rt-PA alone26, 27. The gene discussed is NOS3; the disease is infarction.